Third Class Of Drugs Should Not Be “Completely Closed Down” – Ganley
This article was originally published in The Tan Sheet
Executive Summary
Debate on the merits of a third class of drugs could resurface as FDA considers Rx-to-OTC switch applications of drugs indicated for chronic conditions
You may also be interested in...
FDA Plans Behind-The-Counter Drugs Meeting, Mulls “Transitional” Status
FDA will discuss the idea of behind-the-counter drug sales as a possible transitional stage between Rx and OTC status when it holds a forum on the topic with stakeholders
Third Class Of Drugs Back In The News With Proposed UK Statin Switch
J&J/Merck's application to make Zocor available in the UK without a prescription may revive debate in the U.S. regarding creation of a third class of drugs
Label Comprehension Studies Must Account For Drugs’ Complexity – Bull
The science behind creating OTC labeling and label comprehension studies needs to be improved to account for the increasing complexity of nonprescription drugs and their indications, stated Center for Drug Evaluation & Research Office of Drug Evaluation V Director Jonca Bull, MD